Skip to main content
Clinical Trials/JPRN-UMIN000049194
JPRN-UMIN000049194
Completed
未知

Multicenter retrospective study evaluating the efficacy and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer. - NEJ056

orth East Japan Study Group0 sites200 target enrollmentOctober 13, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
orth East Japan Study Group
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 13, 2022
End Date
March 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
orth East Japan Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\) Patients diagnosed as having small\-cell lung cancer (SCLC), combined SCLC, large\-cell neuroendocrine carcinoma. (2\) In both groups, patients do not meet the eligibility criteria for Durvalumab (e.g. active autoimmune disease, grade 2 or higher pneumonitis from previous CRT) (3\)Patients with distant metastases at diagnosis of recurrence or at initial evaluation after chemoradiotherapy. (4\)Other cases that are determined to be inappropriate by attending physicians. (5\)Patients with active multiple cancers. (6\) Receipt of any investigational new drugs for post\-treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials